EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Emergence of Trichophyton indotineae in Switzerland (2014–2025): Clinical analysis and antifungal susceptibility

Annabel H Lechner, Dennis D Arnold, Philipp P Bosshard iD

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 09.07.2026

DOI: 10.1111/ddg.70394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, online erschienen am 09.07.2026. Verfasst von Annabel H Lechner und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives Trichophyton indotineae is an emerging dermatophyte associated with chronic, recalcitrant dermatophytosis and terbinafine resistance due to squalene epoxidase ( SQLE ) mutations. We analyzed clinical characteristics, antifungal susceptibility profiles, SQLE mutations, and treatment outcomes of cases diagnosed in Switzerland. Patient and methods Clinical and therapeutic data of patients diagnosed at the University Hospital Zurich (2014‐2024) were reviewed. Antifungal susceptibility testing and SQLE gene sequencing were performed for 31 isolates. Additional SQLE data up to December 2025 were analyzed to contextualize temporal trends.

Results

Thirty‐five cases were identified, with a marked increase in recent years. SQLE mutations occurred in 20/31 (65%) study isolates and 55/69 (80%) isolates through 2025, most commonly F397L, L393S, and A448T. Mutated strains exhibited significantly higher terbinafine MICs than wild‐type (median 8 vs. 0.008 µg/ml). Patients with SQLE ‐mutated strains required significantly longer systemic treatment (11.5 vs. 3.5 weeks) and often required itraconazole for eradication, whereas wild‐type infections responded to terbinafine. Relapses occurred in one third of patients but generally responded to retreatment.

Conclusions

Trichophyton indotineae is an emerging cause of dermatophytosis in Switzerland. SQLE genotyping supports individualized therapy; terbinafine remains effective for wild‐type strains, itraconazole represents the most reliable option for SQLE ‐mutated infections.

Schlagwörter

Stichwörter der Autor:innen

Antifungal susceptibility testingTrichophyton indotineaedermatophytosissqualene epoxidase

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Department of Dermatology and Venereology, City Hospital Zurich, Zurich, Switzerland.

ORCID-Profile: Philipp P Bosshard

Zitieren

APA

Lechner, A. H., Arnold, D. D., & Bosshard, P. P. (2026). Emergence of Trichophyton indotineae in Switzerland (2014–2025): Clinical analysis and antifungal susceptibility. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.70394

Vancouver

Lechner AH, Arnold DD, Bosshard PP. Emergence of Trichophyton indotineae in Switzerland (2014–2025): Clinical analysis and antifungal susceptibility. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2026. doi:10.1111/ddg.70394

BibTeX
@article{Lechner2026,
  author = {Lechner, Annabel H and Arnold, Dennis D and Bosshard, Philipp P},
  title = {Emergence of Trichophyton indotineae in Switzerland (2014–2025): Clinical analysis and antifungal susceptibility},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2026},
  doi = {10.1111/ddg.70394}
}
Kostenlos starten →